Qulipta vs Leqembi
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Qulipta | US Leqembi | |
|---|---|---|
| Generic name | atogepant | lecanemab |
| Drug class | CGRP Receptor Antagonist | Anti-Amyloid Monoclonal Antibody |
| Treats | Migraine prevention | Early Alzheimer's disease |
| Category | Neurology | Neurology |
| Manufacturer | AbbVie | Eisai |
| Year approved | 2021 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $120M | — |
| Common side effects | Nausea, Constipation, Fatigue, Decreased appetite | Brain swelling (ARIA), Brain bleeding (ARIA), Infusion reactions, Headache |
Frequently asked questions
Is Qulipta or Leqembi better?
Neither is universally "better." Qulipta (atogepant) and Leqembi (lecanemab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Qulipta and Leqembi?
Qulipta is a CGRP Receptor Antagonist made by AbbVie, while Leqembi is a Anti-Amyloid Monoclonal Antibody made by Eisai. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Qulipta has the larger estimated TV advertising budget of the two.